Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a research note published on Friday morning, Marketbeat reports. The firm issued an overweight rating and a $5.
Cantor Fitzgerald raised the firm’s price target on MicroStrategy (MSTR) to $613 from $581 and keeps an Overweight rating on the shares.
Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...
Cantor Fitzgerald is charged with violating antifraud and proxy provisions. Former Comtech CEO is charged with insider trading ahead of negative earnings. The Securities and Exchange Commission on ...
Analysts at Cantor Fitzgerald initiated coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) in a note issued to investors on Friday, MarketBeat.com reports. The brokerage ...
Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The most substantial contributor to the rating is the parent firm's five-year risk-adjusted success ratio of ...
Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...
The nomination of Howard Lutnick, chairman and CEO of financial services firm Cantor Fitzgerald, as Commerce Secretary signals a new chapter for the USPTO.
Cantor Fitzgerald International Eq Fund earns an Above Average Process Pillar rating. The primary contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback